Dupilumab
Patients in UK to be given early access to Sanofi’s eczema treatment
March 14, 2017Research and Development, Sales and Marketing Dupilumab, MHRA, Sanofi
Sanofi’s treatment for atopic dermatitis, otherwise known as eczema, has been given a positive scientific opinion through the MHRA’s Early …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment
April 1, 2016Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
Positive news for Sanofi asthma drug
May 23, 2013Sales and Marketing Dupilumab, Regeneron, Sanofi, asthma
An asthma drug being developed by Sanofi and Regeneron Pharmaceuticals has performed well in a Phase IIa trial, reducing the …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
